Teva Pharmaceutical Industries (NYSE:TEVA) announces the
availability of the autoinjector device for migraine med Ajovy
(fremanezumab-vfrm) at a wholesale acquisition cost (WAC) of $603.20.
The FDA approved the drug in September 2018 and the autoinjector in January of this year.
The company says the autoinjector is also available in Germany and will be available soon in certain other European markets.
https://seekingalpha.com/news/3564611-teva-launches-ajovy-autoinjector-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.